MedTrace Logo

Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma

NCT04553458 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 407

Last updated 2020-09-17

No results posted yet for this study

Summary

EASL and mRECIST criteria differ from each other in terms of the number of target lesions (all versus \< = 2) and calculation method (bidimensional versus unidimensional). Therefore, the investigators aimed to retrospectively analyze and compare the clinical outcomes among patients with hepatocellular carcinoma who were treated with different modalities of therapy according to the BCLC classification, and detect the possible predictors of post-treatment outcomes.

Conditions

Interventions

DEVICE

Radiofrequency ablation

Radiofrequency ablation of the tumour

DRUG

Trance-arterial chemoembolization

Trance-arterial chemotherapy

PROCEDURE

Liver resection

non-anatomical or anatomical liver resection

COMBINATION_PRODUCT

Combined radiofrequency ablation + percutaneous ethanol injection

combined therapy

DRUG

Percutaneous ethanol injection

Percutaneous ethanol injection of HCC

DRUG

Systemic chemotherapy

Systemic chemotherapy

DRUG

Sorafenib

Sorafenib

DIETARY_SUPPLEMENT

Viscum

Viscum for HCC

DRUG

Symptomatic treatment

Symptomatic treatment

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Emad A. Ahmed, MD, PhD · Sohag University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2020-06-30
Completion
2020-06-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04553458 on ClinicalTrials.gov